Biogen (BIIB) News Today

Biogen logo
$247.13 -4.28 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$243.25 -3.88 (-1.57%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is Biogen Down Today?

Biogen Inc. (NASDAQ: BIIB) has fresh positive Alzheimer’s data, but investor reaction may be tempered by concerns that recent pipeline progress and growth are already reflected in the stock’s valuation.

  • Positive Sentiment: At CTAD 2026, Biogen and Eisai reported that lecanemab (LEQEMBI) slowed clinical decline over 18 months in early Alzheimer’s patients with α-synuclein co-pathology. The subgroup analysis found reductions in decline versus placebo across several measures, though it was exploratory and post hoc. Clarity AD CSF substudy findings
  • Positive Sentiment: New three-year real-world LEQEMBI findings showed a 76% lower rate of progression to moderate or severe Alzheimer’s dementia versus a matched natural-history cohort. If confirmed, the results could support the drug’s commercial opportunity. Three-year real-world LEQEMBI data
  • Positive Sentiment: Biogen also reported encouraging two-year Phase 2 results for diranersen in early Alzheimer’s, adding to its longer-term Alzheimer’s pipeline prospects. Diranersen two-year data
  • Neutral Sentiment: The α-synuclein results came from a limited subgroup (82 patients) and a post hoc analysis, so they may be less conclusive than findings from a prospective trial. Clarity AD analysis details
  • Negative Sentiment: A recent analyst commentary downgraded Biogen, arguing that M&A-driven growth and Alzheimer’s progress may already be priced in. Another report described analyst views as mixed, potentially limiting enthusiasm despite the favorable data. Biogen rating downgrade commentary
Posted 3h agoAI Generated. May Contain Errors.

Biogen Latest News

Investors Purchase High Volume of Biogen Put Options (NASDAQ:BIIB)
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Biogen Inc. $BIIB Stake Boosted by Cibc World Market Inc.
Biogen: 3 Key Takeaways for Long-Term Investors
Biogen Sees Unusually Large Options Volume (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) Upgraded at Wall Street Zen
Biogened Pays Dividend for 2025 Financial Year
Biogen Inc. $BIIB Stake Lifted by Danske Bank A S
Biogen Inc. $BIIB Stock Acquired by Fifth Third Bancorp

Biogen Media Mentions By Week

Biogen Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BIIB
News Sentiment
▼
0.76

0.39
▲
Average
Healthcare
News Sentiment

Biogen News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BIIB Articles
This Week
▼
48

11
▲
BIIB Articles
Average Week

Biogen Trends on MarketBeat

This week vs. last week
New Followers
1
-50%
Searches
2
-33%
Page Views
3,240
+21%
Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Biogen dated 11/19/2026.
From Our Partners